Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.

Stoops WW, Lofwall MR, Nuzzo PA, Craig LB, Siegel AJ, Walsh SL.

Psychopharmacology (Berl). 2012 Oct;223(4):427-38. Epub 2012 May 24.

2.

Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users.

Stoops WW, Glaser PE, Rush CR.

Psychopharmacology (Berl). 2013 Jul;228(2):255-62. doi: 10.1007/s00213-013-3031-y. Epub 2013 Feb 21.

3.

Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.

Carroll CP, Walsh SL, Bigelow GE, Strain EC, Preston KL.

Exp Clin Psychopharmacol. 2006 May;14(2):109-20.

PMID:
16756415
4.

Mu opioid mediated discriminative-stimulus effects of tramadol: an individual subjects analysis.

Strickland JC, Rush CR, Stoops WW.

J Exp Anal Behav. 2015 Mar;103(2):361-74. doi: 10.1002/jeab.137. Epub 2015 Feb 9.

5.

Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.

Walsh SL, Chausmer AE, Strain EC, Bigelow GE.

Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2.

6.

Physical dependence potential of daily tramadol dosing in humans.

Lanier RK, Lofwall MR, Mintzer MZ, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2010 Sep;211(4):457-66. doi: 10.1007/s00213-010-1919-3. Epub 2010 Jun 30.

7.

Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.

Preston KL, Bigelow GE.

J Pharmacol Exp Ther. 1993 Feb;264(2):813-23.

PMID:
7679737
8.

Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans.

Schuh KJ, Walsh SL, Stitzer ML.

Psychopharmacology (Berl). 1999 Jul;145(2):162-74.

PMID:
10463317
11.

Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.

Walsh SL, Sullivan JT, Preston KL, Garner JE, Bigelow GE.

J Pharmacol Exp Ther. 1996 Nov;279(2):524-38.

PMID:
8930154
12.

Abuse liability and reinforcing efficacy of oral tramadol in humans.

Babalonis S, Lofwall MR, Nuzzo PA, Siegel AJ, Walsh SL.

Drug Alcohol Depend. 2013 Apr 1;129(1-2):116-24. doi: 10.1016/j.drugalcdep.2012.09.018. Epub 2012 Oct 23.

13.

Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.

Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, Yoburn BC.

Eur J Pharmacol. 2008 Nov 12;597(1-3):39-45. doi: 10.1016/j.ejphar.2008.08.025. Epub 2008 Aug 30.

14.

Discriminative stimulus effects of tramadol in humans.

Duke AN, Bigelow GE, Lanier RK, Strain EC.

J Pharmacol Exp Ther. 2011 Jul;338(1):255-62. doi: 10.1124/jpet.111.181131. Epub 2011 Apr 5.

15.

Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans.

Walsh SL, Strain EC, Abreu ME, Bigelow GE.

Psychopharmacology (Berl). 2001 Sep;157(2):151-62.

PMID:
11594439
16.

Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.

Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):57-65. doi: 10.1016/j.drugalcdep.2011.10.018. Epub 2011 Nov 12.

17.

Modest opioid withdrawal suppression efficacy of oral tramadol in humans.

Lofwall MR, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2007 Oct;194(3):381-93. Epub 2007 Jul 1.

PMID:
17605004
18.

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.

Nasser AF, Greenwald MK, Vince B, Fudala PJ, Twumasi-Ankrah P, Liu Y, Jones JP 3rd, Heidbreder C.

J Clin Psychopharmacol. 2016 Feb;36(1):18-26. doi: 10.1097/JCP.0000000000000434.

19.

Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.

Lofwall MR, Babalonis S, Nuzzo PA, Siegel A, Campbell C, Walsh SL.

Drug Alcohol Depend. 2013 Nov 1;133(1):188-97. doi: 10.1016/j.drugalcdep.2013.05.010. Epub 2013 Jun 4.

20.

Supplemental Content

Support Center